Differentiation therapy in poor risk myeloid malignancies: Results of companion phase II studies

Kelly J. Norsworthy,Eunpi Cho,Jyoti Arora,Jeanne Kowalski,Hua-Ling Tsai,Erica Warlick,Margaret Showel,Keith W. Pratz, Lesley A. Sutherland,Steven D. Gore,Anna Ferguson,Sarah Sakoian,Jackie Greer,Igor Espinoza-Delgado,Richard J. Jones,William H. Matsui,B. Douglas Smith

Leukemia Research（2016）

引用 11|浏览65

暂无评分

摘要

•Myeloid growth factors enhance the leukemic activity of differentiation agents in vitro.•GM-CSF plus either bexarotene or entinostat demonstrated differentiation activity in heavily pretreated AML and MDS.•GM-CSF in combination with either bexarotene or entinostat has an acceptable toxicity profile in previously treated AML and MDS.

查看译文

关键词

Differentiation,Acute myeloid leukemia,Myelodysplastic syndrome,Bexarotene,Entinostat

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要